A Look at How These Pfizer Drugs Have Performed in 2017

In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Celebrex reported revenues of $61 million and $150 million, respectively, compared to $33 million and $162 million in 3Q16.

During the first nine months of 2017, Celebrex reported revenues of $564 million compared to $550 million in the first nine months of 2016. Celebrex’s peers in the rheumatoid arthritis drugs market include Roche’s (RHHBY) Rituxan, Bristol-Myers Squibb’s (BMY) Orencia, and Johnson & Johnson’s (JNJ) Remicade. In 3Q17, Rituxan and Orencia reported revenues of $1.8 billion and $632 million, respectively.

In 3Q17, Vfend generated revenues of $97 million, a ~31% decline on a YoY basis and a 4% decline on a quarter-over-quarter basis. In 3Q17, Vfend generated revenues of $94 million from the international market compared to $134 million in 3Q16. Vfend reported revenues of $305 million in the first nine months of 2017 compared to $459 million in the first nine months of 2016.

In 3Q17, Pristiq reported revenues of $69 million, a ~60% decline on a YoY basis and a 50% increase on a quarter-over-quarter basis. In 3Q17, Pristiq generated revenues of $26 million and $43 million from sales in the US and international markets, respectively, compared to $138 million and $36 million in 3Q16. Pristiq reported revenues of $230 million in the first nine months of 2017 compared to $546 million in the first nine months of 2016

In 3Q17, Zyvox reported revenues of $68 million, a ~28% decline on a YoY basis and a 9% decline on a quarter-over-quarter basis. In 3Q17, in the international markets, Zyvox generated revenues of $62 million compared to $76 million in 3Q16.

Zyvox reported revenues of $220 million in the first nine months of 2017 compared to $334 million in the first nine months of 2016.

In 3Q17, Revatio generated revenues of $58 million, a ~21% decline on a YoY basis and a 13% decline on a quarter-over-quarter basis. In 3Q17, Revatio generated revenues of $27 million and $31 million from the US and international markets, respectively, compared to $25 million and $48 million in 3Q16.

Revatio reported $189 million in the first nine months of 2017 compared to $213 million in the first nine months of 2016.

The SPDR S&P Pharmaceuticals ETF (XPH) invests ~4.8% of its total portfolio holdings in Pfizer.